Contract research organisation (CRO) and small scale active pharmaceutical ingredient (API) specialist, Onyx Scientific, has supported biotech company, TopiVert, in the initiation of clinical trials for two narrow spectrum kinase inhibitor (NSKI) drug candidates.
Speed up
These next-generation medicines are aimed at treating chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. Both NSKI drug candidates target several important kinases in signalling cascades in inflammatory cells. The results of the clinical studies are expected in the second half of the year.
“We have been working with Onyx Scientific for several years and they have consistently delivered high quality API for IND-enabling toxicology studies and early phase clinical trials on time and in a cost-effective manner,” said Matthew Fyfe, head of chemistry at TopiVert. “Supported by their technical team, we have been able to accelerate, scale-up and produce GMP batches, which are now being used in our clinical trials. It has been a great collaboration all round.”
“We have supported TopiVert from a very early stage and are really pleased to see them progress their compounds into clinical trials,” added Denise Bowser, commercial director at Onyx Scientific. “They are a great example of a drug developer that has been able to speed up the development process by utilising our integrated approach with regards to solid state chemistry, salt screening, GMP synthesis and API manufacturing.”
